ReviewIndian pacing and electrophysiology journal
Meta-analysis of the safety of outpatient Sotalol initiation in clinical practice.
Review in Indian pacing and electrophysiology journal. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSotalol is a class III anti-arrhythmic medication commonly used in maintaining sinus rhythm in patients with arrhythmias, most notably atrial fibrillation. Sotalol is conventionally initiated in an inpatient setting (typically three days) to allow close monitoring of its effects, particularly corrected QT interval (QTc) prolongation, which may predispose patients to fatal arrhythmias such as torsades de pointes.
objectiveIn this meta-analysis, we aimed to assess the safety of initiating sotalol in an outpatient setting.
methodsWe searched PubMed, Scopus, Embase, Cochrane Library, Web of Science, Virtual Health Library, and Google Scholar for observational studies and randomized controlled trials assessing the safety of outpatient initiation of sotalol until January 2026. Our endpoints were the change from baseline in QTc interval at the longest follow-up and the rate of sotalol discontinuation due to adverse events. Standardized mean differences from baseline in QTc interval with 95% confidence intervals were pooled with a random-effects model using CMA V3 software.
resultsWe included three observational studies with a total cohort of 1248 patients. At the longest follow-up post-sotalol initiation in an outpatient setting, there was no statistically significant change in QTc interval from baseline (SMD = +0.15, 95% CI: -0.357 to 0.658, p = 0.56). Across 1140 patients, the rate of drug discontinuation due to adverse events at one-month post-sotalol initiation ranged from 4.7% (41/880 patients; 95% CI 3.4%-6.3%) in one study to 8.1% (21/260 patients; 95% CI 5.3%-12.1%) in another.
conclusionIn carefully selected patients, the initiation of sotalol in an outpatient setting appears to be safe and associated with no significant adverse events. However, the current evidence is limited to a small number of observational cohorts, and large randomized controlled trials are warranted to establish the safety and efficacy of outpatient sotalol initiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.